Last edition
News about "NATCO Pharma"
NATCO Pharma has secured approval for generic Everolimus tablets for oral suspension. The company’s marketing partner for the ANDA, Breckenridge Pharmaceutical plans to launch it in the US market immediately.
NATCO Pharma | 30/01/2025 | By Abha
NATCO Pharma Announces Investment of USD 8 Million in eGenesis
The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.
NATCO Pharma | 04/09/2024 | By Aishwarya | 122
Natco Pharma Submits ANDA for Generic Version of TABRECTA
Natco claims to be the first company to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of the potential launch of the product under certain circumstances.
Natco Pharma | 31/08/2024 | By Aishwarya | 147
Natco Pharma | 24/04/2023 | By Sudeep Soparkar | 655
NATCO launches additional strengths for generic version of Revlimid in US
The generic version of Revlimid (lenalidomide capsules) are of strengths in 2.5 mg, and 20 mg
NATCO Pharma | 11/03/2023 | By Sudeep Soparkar | 580
NATCO submits ANDA with US FDA for Olaparib tabs in US
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostate cancer.
NATCO Pharma | 15/02/2023 | By Sudeep Soparkar | 449
US FDA completes inspection of Natco's Vizag formulation facility
The facility received two observations, one on the written production process control procedure and the other on the investigation procedure
Natco Pharma | 06/02/2023 | By Sudeep Soparkar | 696
NATCO Pharma launches Pomalyst caps in Australia
The product was launched by NATCO’s commercial partner Juno Pharmaceuticals
NATCO Pharma | 09/11/2022 | By Sudeep Soparkar | 678
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy